Best Selank Source: Testing Is 20 Points, Price Is 10

Five factors, weighted by how much each one changes the risk of the purchase rather than by how often vendors advertise it.

Testing scope takes 40% of the total because it is the only factor that can fail invisibly. A short fill shows up on a scale, a slow dispatch shows up in tracking, an opaque price shows up at checkout. Endotoxin does not show up at all.

Price transparency is deliberately not the same thing as a low price. A supplier publishing list, code and tiers on the page scores full marks whether the resulting rate is $2.38 or $6.00 per milligram, because transparency is what makes the rate comparable. The same separation is applied on our MOTS-c source ranking, which scores on cost per milligram rather than vial price for the same reason.

Some failures are not point deductions. A supplier failing either gate below is not a low-scoring source, it is an unscoreable one, and the remaining factors do not get computed.

• Gate one: a named external laboratory, publishing lot-level documents. In-house quality control is not third-party testing, and a single site-wide PDF covering every batch ever sold is not a batch certificate. Without a named laboratory and a lot code there is no way for anyone outside the company to check any claim it makes, and the other four factors become self-reported.
• Gate two: research-use labelling, with no human-use claims. A seller advertising benefits, routes of administration or suggested quantities for an unapproved substance is making a regulatory decision on your behalf. It also tells you the seller's other statements are marketing rather than description, which is exactly the wrong signal on the factor that carries 20 points.

Gate two eliminates most consumer nootropic storefronts selling Selank nasal spray, and gate one eliminates most of what is left in the grey market. What survives is a small set of research-chemical suppliers, which is why a best Selank vendor list of fifteen names is usually a list of one supplier and fourteen resellers of it.

FDA states, on its page listing bulk drug substances that may present significant safety risks, that compounded drugs containing selank acetate may pose a risk for immunogenicity for certain routes of administration, due to the potential for aggregation and peptide-related impurities, and that it lacks important information regarding any safety issues raised by selank acetate administered to humans.

That sentence contains three distinct testing questions and a purity figure answers only part of one.

• Aggregation and impurities. Chromatography sees these. A purity percentage with a peak list behind it is real evidence, and the peak list matters: the February certificate for this product shows 99.32% at 7.13 minutes and a second peak of 0.68% at 6.36 minutes, which against a measured 12.29 mg is roughly 84 micrograms per vial of unidentified UV-detected material.
• Endotoxin. Chromatography is blind to it. Endotoxin is lipopolysaccharide debris from Gram-negative bacteria and it survives the conditions that kill the bacteria, which is why a bacterial endotoxins test by LAL is a separate assay with its own units.
• Microbial contamination. A third question again, because sterility and endotoxin are not the same test and passing one says nothing about the other.

Scoring testing scope therefore means scoring which of those three a supplier answers for your lot, not whether it uses the word tested. The equivalent argument on a compound where FDA has documented actual adverse events traced to endotoxin is set out in our NAD+ source ranking, and it is the reason both scorecards put this factor first.

Ascension Peptides, scored against the five factors, with the evidence named so the arithmetic can be argued with.

Total 42 of 50. Both gates passed.

The 6 points lost sit almost entirely in one row, and the row is the heaviest one. Six of the six missing points come from testing scope being lot-dependent: buy the vial covered by the June certificate and the evidence package is close to complete, buy the one covered by the February certificate and three of the tests are simply absent. That is not a flaw in a supplier so much as a fact about this market, and it is why the practical advice is to read the certificate matching your lot code rather than the first one on the page.

A scorecard is only useful if it says what would change it. Three things would.

• Endotoxin and sterility on every published lot. Worth the remaining 6 points on testing scope outright, and it is achievable: the same supplier already commissions that panel from Kovera Labs, so it is a matter of scope per batch rather than of capability.
• Compendial sterility testing rather than a rapid screen. The Kovera report itself notes that its method is a preliminary assessment suitable for quality control and that full compendial testing may be required for regulatory compliance. That is a candid disclosure and it is also a ceiling on what the screen proves.
• A documented answer on stacking. One point, and the cheapest of the three to fix.

Three things would not move it at all: a lower headline price, a longer list of testimonials, and a larger range. The best place to buy Selank is decided by what a supplier can prove about a specific vial, and none of those three proves anything. Our retatrutide source ranking reaches its verdict the same way, on documents rather than on reputation.

• A certificate describes a sampled aliquot on a date. Filling, capping, storage and transit all happen afterwards. A document is evidence about a batch, not about the vial in your hand.
• Nothing here clears anything for use in a person. An endotoxin figure ranks two suppliers against each other. FDA's statement that it lacks important information about safety issues raised by administration to humans is untouched by any laboratory report, and Selank holds no FDA approval for any indication.
• Regulatory status is not a quality signal in either direction. Selank appears in no category of the 503A bulk drug substances list. It was nominated and the nomination was withdrawn. It is not in Category 2, which currently holds six substances, none of them Selank. Unlisted means unlisted, not endorsed and not banned, and our Selank legal position page works through what that leaves.
• The assayed masses are results, not terms. $23.75 over the labelled 10 mg is $2.38 per milligram. Over 12.29 mg it is $1.93 and over 11.86 mg it is $2.00, but no listing promises an overfill, so compare suppliers on $2.38.

Past that point the question stops being about vendors. A 10 mg vial reconstituted at 2 mL is 5 mg/mL, so one unit on a U-100 barrel holds 50 micrograms, as laboratory handling arithmetic only. The Selank calculator, our reference sources page and the Selank price breakdown take it from there.